FDA MedWatch Alert

Sent to subscribers of: azithromycin systemic

FDA Statement: Zithromax (azithromycin) - Risk of Cardiovascular Death

May 17, 2012

Audience: Primary Care, Pharmacy.

ISSUE: FDA notified healthcare professionals that it is aware of the study published in the New England Journal of Medicine May 17, 2012 reporting a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. FDA is reviewing the results from this study and will communicate any new information on azithromycin and this study or the potential risk of QT interval prolongation after the agency has completed its review.

Read more...